ArticleJournal of the American Heart Association2023
Uric Acid Levels, Number of Standard Modifiable Cardiovascular Risk Factors, and Prognosis in Patients With Coronary Artery Disease: A Large Cohort Study in Asia.
Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Increased Xanthine Oxidoreductase Activity in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.CHEST pulmonary · 2026Article
- Beyond the Usual Suspects: A Narrative Review of High-Yield Non-Traditional Risk Factors for Atherosclerosis.Journal of clinical medicine · 2026Review
- Gout, Uric Acid, and Coronary Artery Disease.Journal of atherosclerosis and thrombosis · 2025Review
- Elevated serum uric acid as an independent risk factor for multiple stent placement in non-hypertensive, non-diabetic patients with coronary artery disease: a retrospective cohort analysis.Clinical rheumatology · 2025Article
- Development and Validation of an Explainable Prediction Model to Assess the Risk of Coronary Artery Disease in Young and Middle-Aged Individuals.Reviews in cardiovascular medicine · 2025Article
- Predictive value of TG/HDL-C and GFR-adjusted uric acid levels on cardiovascular mortality: the URRAH study.Lipids in health and disease · 2025Article
- Validation of the role of apolipoproteins in coronary artery disease patients with impaired kidney function for prognosis: a prospective cohort study in China.Nutrition journal · 2025Article
- Gender differences in the prognostic impact of uric acid in patients with heart failure and preserved ejection fraction.BMC cardiovascular disorders · 2025Article
- The impact of serum uric acid on biological aging and mortality risk: insights from the NHANES and CHARLS cohorts.Frontiers in nutrition · 2025Article
- Association of SMuRFs with cardiovascular risk factors, disease burden, and pharmacological management in Middle Eastern patients with ASCVD and a family history of premature CVD.Frontiers in cardiovascular medicine · 2025Article
- Comparison of different insulin resistance surrogates in predicting hyperuricemia in non-diabetic Yi residents in Yunnan Province.Frontiers in endocrinology · 2025Article
- Elevated uric acid to serum albumin ratio: a predictor of short-term outcomes in Chinese heart failure patients.Frontiers in nutrition · 2024Article
- Association of Serum Uric Acid with Non-Valvular Atrial Fibrillation: A Retrospective Study in China.International journal of general medicine · 2024Article
- Cardiovascular Risk Factors in Patients with Valvular Heart Disease: A Nationwide Observational Cohort Study.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Serum uric acid (UA) is correlated closely with traditional cardiovascular risk factors, which might interfere with the action of UA, in patients with coronary artery disease. We performed this study to evaluate the prognostic effect of UA levels in individuals with different numbers of standard modifiable cardiovascular risk factors (SMuRFs). Methods and Results In this prospective study, we consecutively enrolled 10 486 patients with coronary artery disease. They were stratified into 3 groups according to the tertiles of UA concentrations and, within each UA tertile, further classified into 3 groups by the number of SMuRFs (0-1 versus 2-3 versus 4). The primary end point was major adverse cardiovascular and cerebrovascular events (MACCEs), including death, myocardial infarction, stroke, and unplanned revascularization. Over a median follow-up of 2.4 years, 1233 (11.8%) MACCEs were recorded. Patients with high UA levels developed significantly higher risk of MACCEs than those with low UA levels. In addition, UA levels were positively associated with MACCEs as a continuous variable. More importantly, in patients with 0 to 1 SMuRF, the risks of MACCEs were significantly higher in the high-UA-level group (adjusted hazard ratio [HR], 1.469 [95% CI, 1.197-1.804]) and medium-UA-level group (adjusted HR, 1.478 [95% CI, 1.012-2.160]), compared with the low-UA-level group, whereas no significant association was found between UA levels and the risk of MACCEs in participants with 2 to 3 or 4 SMuRFs. Conclusions In patients with coronary artery disease who received evidence-based secondary prevention therapies, elevated UA levels might affect the prognosis of individuals with 0 to 1 SMuRF but not that of individuals with ≥2 SMuRFs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.